Agency IQ

JANUARY 26, 2024

Class A devices needed to be IVDR-ready on the original date (May 26, 2022), but class D had until May 2025, class C until May 2026, and class B and sterile class A until May 2027. In-house tests (in the U.S. called laboratory-developed tests manufactured and used in a single lab) had until May 26, 2024.

Regulations 40

Regulations Compliance Laboratories Production 40

Perficient: Drug Development

AUGUST 12, 2023

The AI market is projected to reach $407B by 2027, which is substantial growth from its $86.9B This is what everyone is talking about in the market, and I couldn’t be more excited to learn not just about Salesforce AI capabilities, but how we can understand and trust AI more effectively. in revenue in 2022.

Marketing 52

Marketing 52

FDA Law Blog: Biosimilars

OCTOBER 6, 2023

The Proposed Rule states that Stage 4 and Stage 5 would not begin before October 1, 2027, and April 1, 2028, respectively, in order to enable laboratories to participate in negotiations preceding user fee reauthorization in 2027 (taking effect in FY2028, which begins on October 1, 2027).

Laboratories 62

Laboratories FDA Regulations Production 62

LifeSciVC

APRIL 26, 2024

Fourth, the venture exit environment circa 2027-2030 for the new crop of early stage startups being created today will likely have structural supply/demand elements more favorable than the backdrop in recent years. Fewer startups over time should ameliorate this crowding dynamic to some extent.

DNA 110

DNA Science Marketing Clinical Trials 110

Perficient: Drug Development

DECEMBER 27, 2023

The effective date of the new rule is April 1, 2024, with key provisions taking effect on January 1, 2026, and January 1, 2027. Banks Additionally, the recent rule by the OCC, the Federal Reserve, and the FDIC strengthens and modernizes Community Reinvestment Act (CRA) regulations.

Compliance 52

Compliance Regulations Production 52

The Pharma Data

MAY 2, 2022

Amgen made continued progress last year toward its goal of achieving carbon neutrality in our operations by 2027 3. A Healthy Amgen: We hold ourselves to high?standards standards in our?operations operations – working to?ensure ensure our actions and culture reflect Amgen?values.

Government 40

Government Science Disease 40

FDA Law Blog: Biosimilars

NOVEMBER 22, 2023

Moreover, California recently enacted the California Food Safety Act , prohibiting the manufacturing, selling, delivering, distributing, or holding food that contains BVO, with a $5,000 civil penalty for first violations, as of January 1, 2027. In addition, New York introduced a similar bill prohibiting certain food additives, including BVO.

FDA 52

FDA Production Regulations 52

The Premier Consulting Blog

OCTOBER 1, 2023

PDUFA VII will be in effect from fiscal year 2023 through fiscal year 2027. It is the sixth reauthorization of PDUFA that provides the FDA with necessary resources and includes provisions to increase the efficiency of the drug development process. Check out our previous blog post to learn more about changes that came in PDUFA VII.

FDA 52

FDA Packaging Drug Development Drugs 52

FDA Law Blog: Biosimilars

MAY 13, 2024

Further, FDA has stated that enabling advanced data analytics, including RWD, is one of the objectives incorporated in the FDA’s Information Technology Strategy for FY 2024-2027. We, and many stakeholders, agree that RWD and RWE can play an invaluable role.

FDA 109

FDA Production Trials Pharmacy 109

FDA Law Blog: Biosimilars

JUNE 14, 2023

In FY 2026 – FY 2027, continue to support products enrolled in previous fiscal years and expand to enroll up to 100 additional products each fiscal year within existing OHTs or expand to additional OHTs, depending on lessons learned from FY 2023 – FY 2025 experience (i.e., up to 125 total products enrolled through FY 2025).

Production 44

Production FDA Clinical Trials Marketing 44

The Pharma Data

SEPTEMBER 27, 2021

5.500% Notes due 2027 532457 AZ1 7 0.750% due August 31, 2026 0.820% 40 bps $1,226.23 3.100% Notes due 2027 532457 BP2 13 0.750% due August 31, 2026 0.820% 35 bps $1,100.66 5.500% Notes due 2027 532457 AZ1 7 0.750% due August 31, 2026 0.820% 40 bps $1,226.23

Disease 52

Disease Marketing 52

FDA Law Blog: Biosimilars

OCTOBER 12, 2023

Priority is given to Suitability Petitions that could mitigate or resolve a drug shortage; address a public health emergency declared by HHS; mitigate waste by way of new strengths for parenteral products; or subject to special review under the President’s Emergency Plan for Aids Relief.

FDA 57

FDA Drugs Production 57

The Pharma Data

SEPTEMBER 7, 2021

5.500% Notes due 2027. 3.100% Notes due 2027. 284,112,000. 1.750% due August 15, 2041. 5.550% Notes due 2037. 532457 BA5. 476,152,000. 1.750% due August 15, 2041. 532457 AZ1. 377,505,000. 0.750% due August 31, 2026. 4.650% Notes due 2044. 532457 BG2. 43,016,000. 1.750% due August 15, 2041. 3.950% Notes due 2047. 532457 BR8. 532457 BV9.

Licensing 52

Licensing Licensing Marketing 52

FDA Law Blog: Biosimilars

AUGUST 23, 2023

A DHT is considered “a system that uses computing platforms, connectivity, software, and sensors for healthcare and related uses.”

Production 52

Production Clinical Trials FDA Drugs 52

The Pharma Data

SEPTEMBER 27, 2021

Acceptance Priority Level Principal Amount Outstanding Principal Amount Tendered Approximate Percentage of Outstanding Amount Tendered Anticipated Principal Amount to be Accepted for Purchase 4.150% Notes due 2059 532457 BU1 1 (1) $1,000,000,000 $408,714,000 40.87% $408,714,000 3.950% Notes due 2049 532457 BT4 2 (2) $1,500,000,000 $541,847,000 36.12% (..)

Marketing 40

Marketing Disease 40

The Pharma Data

FEBRUARY 22, 2022

In January 2021, Amgen announced plans to achieve carbon neutrality in its operations by 2027 , while further reducing water use by 40% and waste disposed by 75%. 1 These reductions were achieved even as the Company increased production capacity, expanded its presence to approximately 100 countries, and grew revenues significantly.

Government 52

Government International Production Science 52

The Pharma Data

NOVEMBER 29, 2021

” Amgen’s four ESG pillars – Healthy People, Healthy Society, Healthy Environment and a Healthy Amgen – include commitments to: Achieve carbon neutrality by 2027, along with a 40% reduction in water used and a 75% reduction in waste disposed.

Government 52

Government Clinical Trials Science Trials 52

Vial

FEBRUARY 29, 2024

The Clinical Trials Outsourcing Market – Global Outlook & Forecast 2022-2027 report lists the following key trends in the future of the CRO global market. A rise of clinical trial outsourcing due to cost management, globalization, and digitalization.

Clinical Trials 52

Clinical Trials Trials Clinical Research Drug Development 52

Drug Target Review

JUNE 5, 2023

How does Zymeworks plan to advance at least five novel medicines into clinical studies by 2027 under its ZYME 5×5 R&D objectives? We continue our in-house development strategy of accelerating our time from preclinical development candidate selection through IND filing.

Treatment 100

Treatment Pharmacokinetics Drugs Cell Biology 100

FDA Law Blog: Biosimilars

JUNE 7, 2023

Recall that CMS will require manufacturers of selected drugs to negotiate a maximum fair price (“MFP”) with the agency according to the following timeline (the dates apply from applicable year 2027 onwards).

Government 44

Government Compliance Drugs Production 44

The Pharma Data

FEBRUARY 18, 2022

” Amgen’s four ESG pillars – Healthy People, Healthy Society, Healthy Planet, and a Healthy Amgen – include commitments to: Achieve carbon neutrality by 2027, along with a 40% reduction in water used and a 75% reduction in waste disposed.

Government 40

Government Clinical Trials Science Trials 40

The Pharma Data

MARCH 7, 2022

The new facility will also be built to exacting environmental standards, consistent with the company’s goal of reducing water usage and waste and achieving carbon neutrality by 2027. Construction management and design services for this new state-of-the-art facility are being led by Integrated Project Services, LLC.

Science 52

Science Disease Research 52

Advarra

JUNE 13, 2023

between 2020-2027. Per a report from the American Society of Cell and Gene Therapy (ASGCT) , gene therapy research is an increasingly important part of an institution’s research portfolio, with over 3,500 therapies in preclinical or clinical. The accelerating gene therapy market is expected to grow globally by 16.6%

Therapies 52

Therapies Research Clinical Trials Trials 52

Agency IQ

MARCH 15, 2024

The regulation is focused on shifting the plastic pollution burden from consumers to producers, and requires the PRO to remit $500 million to the state each year between 2027 and 2037 for the California Plastic Pollution Mitigation Fund (totaling $5 billion).

Regulations 40

Regulations Packaging Compliance Production 40

The Pharma Data

JANUARY 26, 2021

billion by 2027. . With very limited approved first-line pharmaceutical therapies for HCC available today, challenges include drug resistance, adverse side effects, and high costs. An estimated 700,000 people are diagnosed with HCC each year, with the global market for liver cancer drugs expected to grow to $3.9

FDA 40

FDA Treatment Small Molecule Drugs 40

The Pharma Data

JUNE 26, 2021

To that order and to minimize the potential direct and indirect impacts of its business on the environment throughout the whole lifecycle of its products, the company intends to: protect ecosystems by introducing biodiversity protection plans at all its sites located near sensitive areas by 2025; implement water stewardship and water efficiency plans (..)

Packaging 52

Packaging Vaccine Production Science 52

Agency IQ

MAY 17, 2024

GDUFA III), which reauthorized the program through 2027. The generic drug user fee program is currently on its third iteration (i.e., Under GDUFA III, the Agency agreed to improve and expand upon the various meeting types which generic drug developers can take advantage of to discuss issues relevant to their development programs with FDA.

Science 40

Science FDA Drugs Production 40

The Pharma Data

DECEMBER 14, 2020

Market researchers expect the global market for gene and cell therapy to grow at a CAGR of over 25% through 2027. In the medium term, however, c-LEcta’s management expects demand to develop dynamically, especially from gene and cell therapy. The DENARASE ELISA kit was also launched in 2020 to complement the company’s current products.

Production 52

Production Vaccine Engineering Therapies 52

FDA Law Blog: Biosimilars

JULY 24, 2023

With that decision, Jazz lost its ODE, allowing Avadel’s sodium oxybate product to compete with Jazz’s long before the expiration of the ODE covering Jazz’s most recent product, Xywav, in 2027.

FDA 52

FDA Regulations Clinical Trials Drugs 52

The Pharma Data

APRIL 7, 2021

To reduce its greenhouse gas emissions by 55% by 2030 and contribute to better resource conservation, Sanofi plans to remove all pre-formed plastic packaging (blister packs) for its vaccines by 2027. The company is also committed to ecodesigning all its new products by 2025.

Vaccine 52

Vaccine Packaging Disease Treatment 52

Vial

DECEMBER 7, 2023

billion by 2027 , at a compound annual growth rate (CAGR) of 45.7% As a newer alternative to the time-consuming nature of traditional candidate screening and drug discovery, AI-designed drugs have started to make their mark, promising quick and efficient results. billion in 2022 and is expected to grow to US$4.0 between these years.

Drugs 52

Drugs Clinical Trials Trials Treatment 52

The Pharma Data

JUNE 7, 2022

Those taking up this offer will be required to hold the Shares or the corresponding FCPE units for a period of approximately five years, i.e. until 31 May 2027, except upon the occurrence of an early release event provided for under Article R. The voting rights attached to the subscribed Shares will be exercised directly by the employees.

Regulations 40

Regulations Vaccine Science Treatment 40

FDA Law Blog: Biosimilars

MARCH 5, 2024

To the extent that AstraZeneca alleged that CMS would cause it this type of harm in 2027, the court found that allegation to be too speculative. Because the alleged harm arises from the Act, not from the Guidance, the court found that AstraZeneca did not meet the causation or redressability elements of standing under this argument.

Government 62

Government Marketing Production Drugs 62

The Pharma Data

JANUARY 25, 2021

This activity could increase (or reduce the size of any decrease in) the market price of the Company’s common stock, the notes or the Company’s 2.50% Convertible Senior Notes due 2027 at that time.

Marketing 52

Marketing Disease Clinical Trials Clinical Development 52

Agency IQ

SEPTEMBER 15, 2023

The ban for the intention inclusion of any of these substances in cosmetic product would become effective on January 1, 2027. (CAS RN 84603-73-6) Pyrogallol (CAS RN 87-66-1) C.I. Next steps AB 496 will be sent to the governor for his signature or veto. Once signed it will officially amend California’s HSC.

Regulations 40

Regulations Packaging Production Government 40

The Premier Consulting Blog

NOVEMBER 20, 2023

years after publication; no earlier than October 1, 2027) End of Enforcement Discretion for: Premarket review for high-risk IVDs. Phase 3 (3 years after publication) End of Enforcement Discretion for: QS requirements (good manufacturing practice for medical devices). Phase 4 (3.5

Laboratories 52

Laboratories FDA Clinical Development Regulations 52

Agency IQ

AUGUST 2, 2024

legislation The list below includes legislation proposed by the European Commission that is yet-to-be-published.

Regulations 40

Regulations Clinical Trials Production Trials 40